Blood filtering study for cancer treatment side effects
This study looks at how a procedure called therapeutic plasma exchange (TPE), which filters the blood, affects the levels of immunotherapy (immune checkpoint inhibitor) drugs in the body. It aims to help manage severe side effects from these cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with cancer
- You are taking or recently took an immunotherapy drug (like pembrolizumab, nivolumab, atezolizumab, or similar)
- You have had severe side effects from the immunotherapy that your doctor thinks might be helped by a blood-filtering procedure
- You are already scheduled for or are currently receiving this blood-filtering procedure at the University of Chicago Medicine
- You can have blood samples taken for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This trial studies a treatment called ECP to help immune-related side effects (irAEs) that did not improve with standard steroid treatment. It may help control symptoms and change immune activity to reduce ongoing harm from immunotherapy.
This trial tests a new plasma filter, PX2, used in a procedure called therapeutic plasma exchange (TPE) to clean harmful substances from your blood. It’s for people who already need TPE and can safely use a blood thinner during the treatment.
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
Hear when a new Immune-related Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.